Abatacept for the Treatment of Myositis-associated Interstitial Lung Disease (ATtackMy-ILD)

  • STATUS
    Not Recruiting
  • End date
    May 30, 2023
  • participants needed
    20
  • sponsor
    Rohit Aggarwal, MD
Updated on 20 July 2022
tacrolimus
cyclophosphamide
cyclosporine
methotrexate
immunosuppressive
rituximab
prednisone
anakinra
immunosuppressive agents
infliximab
tumor necrosis factor
etanercept
myositis
pulmonary disease
immunosuppressants
immunosuppression
azathioprine
leflunomide
abatacept
igiv
mycophenolate
intravenous immunoglobulin
tocilizumab
pirfenidone
interstitial lung disease
ciclosporin

Summary

A randomized, controlled pilot trial to evaluate the efficacy and safety of subcutaneous Abatacept in treating interstitial lung disease associated with the anti-synthetase syndrome.

Description

This is a proof of concept study to evaluate the efficacy, safety and tolerability of abatacept in Syn-ILD in a multi-center randomized, placebo-controlled 6-month (24-week) pilot study.

Details
Condition Myositis, Interstitial Lung Disease
Treatment Placebo, Abatacept
Clinical Study IdentifierNCT03215927
SponsorRohit Aggarwal, MD
Last Modified on20 July 2022

Similar trials to consider

Loading...

Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 

 • 

Private

Reply by • Private
Loading...

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.
Loading...

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note